Human leukocyte antigen-B phenotype and minimal residual disease in chronic myeloid leukemia patients treated with imatinib: Is there an association?

2020 ◽  
Vol 9 (2) ◽  
pp. 34
Author(s):  
Najmaldin Saki ◽  
ElhamHomaei Hadad ◽  
Ali Ehsanpour ◽  
Tina Vosoughi
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Human Leukocyte Antigen ◽  
Minimal Residual Disease ◽  
Myeloid Leukemia ◽  
Residual Disease ◽  
Human Leukocyte ◽  
Leukocyte Antigen ◽  
Antigen B ◽  
Minimal Residual

Endogenous Erythroid Colony Formation in Chronic Myeloid Leukemia: A Recurrent Finding Associated with Persistent Minimal Residual Disease Under Imatinib

2013 ◽  
Vol 22 (23) ◽  
pp. 3043-3051 ◽  
Author(s):  
Elisa Einwallner ◽  
Eva Jaeger ◽  
Gerlinde Mitterbauer-Hohendanner ◽  
Martin Bilban ◽  
Ingrid Simonitsch-Klupp ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Minimal Residual Disease ◽  
Colony Formation ◽  
Myeloid Leukemia ◽  
Residual Disease ◽  
Minimal Residual

scholarly journals Manifold-assisted Reverse Transcription-PCR with Real-Time Detection for Measurement of the BCR-ABL Fusion Transcript in Chronic Myeloid Leukemia Patients

2000 ◽  
Vol 46 (7) ◽  
pp. 913-920 ◽  
Author(s):  
Gisela Barbany ◽  
Anette Hagberg ◽  
Ulla Olsson-Strömberg ◽  
Bengt Simonsson ◽  
Ann-Christine Syvänen ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Real Time ◽  
Minimal Residual Disease ◽  
Reverse Transcription ◽  
Myeloid Leukemia ◽  
Residual Disease ◽  
Detection System ◽  
Fusion Transcript ◽  
Mrna Quantification ◽  
Minimal Residual

Abstract Background: BCR-ABL fusion mRNA expression in bone marrow or peripheral blood can be used as a measure of minimal residual disease in patients with chronic myeloid leukemia (CML). Methods: We used an oligo(dT)-coated manifold support to capture the mRNA directly from the cell lysate. After reverse transcription, the cDNA was eluted from the manifold support, and BCR-ABL and GAPDH mRNAs were quantified in real time using the TaqMan fluorogenic detection system. Results: The detection limit of the method was one positive K562 cell among 105 negative cells. GAPDH was chosen as a reference gene based on the low variation between samples from different stages of the disease and the low signal in the absence of reverse transcription. The day-to-day variation of the method (CV) was 32%. In 43 blood samples from 13 CML patients, mRNA quantification agreed well with cytogenetic data. Conclusions: The proposed procedure constitutes a reproducible and sensitive BCR-ABL mRNA quantification method and is suitable to monitor minimal residual disease in CML patients.

scholarly journals Minimal Residual Disease Detected by the PCR in Chronic Myeloid Leukemia

1993 ◽  
Vol 89 (2) ◽  
pp. 108-109 ◽  
Author(s):  
Richard A. Stark ◽  
Patrice Richard ◽  
Agnes Devergie ◽  
Francis Galibert ◽  
Eliane Gluckman
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Minimal Residual Disease ◽  
Myeloid Leukemia ◽  
Residual Disease ◽  
Minimal Residual
Sign in / Sign up

Export Citation Format

Share Document